24/120
1.0 / 5 stars
All 120 Win/Lose results shown below
CRVO Roast Me summary
CervoMed Inc. (CRVO). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCRVO / S&P -21.32% / 15.20% |
LoseCRVO / S&P -95.74% / 15.00% |
LoseCRVO / S&P CRVO unavailable / 50.40% |
| 2026-Q10/3 |
LoseCRVO / S&P -50.13% / -4.33% |
LoseCRVO / S&P -77.56% / 11.30% |
LoseCRVO / S&P CRVO unavailable / 27.70% |
| 2025-Q40/3 |
LoseCRVO / S&P -2.35% / 2.65% |
LoseCRVO / S&P -58.86% / 9.00% |
LoseCRVO / S&P CRVO unavailable / 13.40% |
| 2025-Q31/3 |
WinCRVO / S&P 28.62% / 8.12% |
LoseCRVO / S&P -38.81% / 4.61% |
LoseCRVO / S&P CRVO unavailable / 13.45% |
| 2025-Q20/3 |
LoseCRVO / S&P -31.26% / 10.94% |
LoseCRVO / S&P -19.44% / 4.83% |
LoseCRVO / S&P CRVO unavailable / 10.63% |
| 2025-Q12/3 |
WinCRVO / S&P 291.03% / -4.27% |
WinCRVO / S&P 15.14% / 4.98% |
LoseCRVO / S&P CRVO unavailable / 10.57% |
| 2024-Q41/3 |
LoseCRVO / S&P -83.97% / 2.41% |
WinCRVO / S&P 36.29% / 5.25% |
LoseCRVO / S&P CRVO unavailable / 6.15% |
| 2024-Q31/3 |
LoseCRVO / S&P -14.72% / 5.89% |
WinCRVO / S&P 116.29% / 5.89% |
LoseCRVO / S&P CRVO unavailable / 6.11% |
| 2024-Q21/3 |
LoseCRVO / S&P -26.52% / 4.28% |
WinCRVO / S&P 208.63% / 5.38% |
LoseCRVO / S&P CRVO unavailable / 5.12% |
| 2024-Q11/3 |
WinCRVO / S&P 205.37% / 10.56% |
LoseCRVO / S&P CRVO unavailable / 5.71% |
LoseCRVO / S&P CRVO unavailable / 5.59% |
| 2023-Q41/3 |
WinCRVO / S&P 65.15% / 11.69% |
LoseCRVO / S&P CRVO unavailable / 6.81% |
LoseCRVO / S&P CRVO unavailable / 7.78% |
| 2023-Q30/3 |
LoseCRVO / S&P -7.78% / -3.27% |
LoseCRVO / S&P CRVO unavailable / 7.52% |
LoseCRVO / S&P CRVO unavailable / -5.03% |
| 2023-Q20/3 |
LoseCRVO / S&P -19.52% / 8.74% |
LoseCRVO / S&P CRVO unavailable / 9.50% |
LoseCRVO / S&P CRVO unavailable / -8.57% |
| 2023-Q10/3 |
LoseCRVO / S&P -17.98% / 7.50% |
LoseCRVO / S&P CRVO unavailable / 10.77% |
LoseCRVO / S&P CRVO unavailable / -15.69% |
| 2022-Q41/3 |
LoseCRVO / S&P -5.42% / 7.56% |
LoseCRVO / S&P CRVO unavailable / 11.88% |
WinCRVO / S&P 4.73% / -17.99% |
| 2022-Q30/3 |
LoseCRVO / S&P -19.91% / -4.88% |
LoseCRVO / S&P CRVO unavailable / 13.47% |
LoseCRVO / S&P CRVO unavailable / -1.41% |
| 2022-Q20/3 |
LoseCRVO / S&P -46.56% / -16.10% |
LoseCRVO / S&P CRVO unavailable / 13.71% |
LoseCRVO / S&P CRVO unavailable / 11.04% |
| 2022-Q10/3 |
LoseCRVO / S&P -19.35% / -4.60% |
LoseCRVO / S&P CRVO unavailable / 15.97% |
LoseCRVO / S&P CRVO unavailable / 42.23% |
| 2021-Q40/3 |
LoseCRVO / S&P -39.22% / 11.03% |
LoseCRVO / S&P CRVO unavailable / 15.00% |
LoseCRVO / S&P -96.38% / 96.40% |
| 2021-Q31/3 |
LoseCRVO / S&P -30.14% / 0.58% |
LoseCRVO / S&P CRVO unavailable / 10.77% |
WinCRVO / S&P 89.85% / 69.42% |
| 2021-Q21/3 |
LoseCRVO / S&P -20.65% / 8.55% |
LoseCRVO / S&P CRVO unavailable / 6.58% |
WinCRVO / S&P 169.44% / 51.81% |
| 2021-Q12/3 |
WinCRVO / S&P 15.00% / 6.17% |
LoseCRVO / S&P CRVO unavailable / -1.06% |
WinCRVO / S&P 342.88% / 7.39% |
| 2020-Q41/3 |
LoseCRVO / S&P -4.76% / 12.15% |
LoseCRVO / S&P CRVO unavailable / -3.72% |
WinCRVO / S&P 702.68% / -33.42% |
| 2020-Q31/3 |
LoseCRVO / S&P -14.29% / 8.93% |
LoseCRVO / S&P CRVO unavailable / -2.04% |
WinCRVO / S&P 1169.60% / -27.10% |
| 2020-Q22/3 |
WinCRVO / S&P 206.25% / 20.54% |
LoseCRVO / S&P CRVO unavailable / -0.46% |
WinCRVO / S&P 773.72% / -27.11% |
| 2020-Q11/3 |
LoseCRVO / S&P -30.43% / -19.60% |
LoseCRVO / S&P CRVO unavailable / 3.47% |
WinCRVO / S&P 350.58% / -14.75% |
| 2019-Q41/3 |
LoseCRVO / S&P -75.14% / 9.07% |
LoseCRVO / S&P CRVO unavailable / 5.36% |
WinCRVO / S&P 106.84% / 2.99% |
| 2019-Q31/3 |
LoseCRVO / S&P -35.09% / 1.70% |
LoseCRVO / S&P CRVO unavailable / 5.02% |
WinCRVO / S&P 26.28% / 0.21% |
| 2019-Q21/3 |
LoseCRVO / S&P -23.18% / 4.30% |
LoseCRVO / S&P CRVO unavailable / 6.64% |
WinCRVO / S&P 73.75% / 8.65% |
| 2019-Q12/3 |
WinCRVO / S&P 86.43% / 13.65% |
LoseCRVO / S&P CRVO unavailable / 8.12% |
WinCRVO / S&P 261.51% / 14.29% |
| 2018-Q40/3 |
LoseCRVO / S&P -69.15% / -13.52% |
LoseCRVO / S&P CRVO unavailable / 9.05% |
LoseCRVO / S&P CRVO unavailable / 18.23% |
| 2018-Q30/3 |
LoseCRVO / S&P -6.52% / 7.71% |
LoseCRVO / S&P CRVO unavailable / 10.21% |
LoseCRVO / S&P CRVO unavailable / 19.06% |
| 2018-Q20/3 |
LoseCRVO / S&P -16.36% / 3.43% |
LoseCRVO / S&P CRVO unavailable / 9.03% |
LoseCRVO / S&P CRVO unavailable / 14.46% |
| 2018-Q10/3 |
LoseCRVO / S&P -53.39% / -0.76% |
LoseCRVO / S&P CRVO unavailable / 7.68% |
LoseCRVO / S&P CRVO unavailable / 12.46% |
| 2017-Q40/3 |
LoseCRVO / S&P -28.92% / 6.64% |
LoseCRVO / S&P CRVO unavailable / 7.03% |
LoseCRVO / S&P CRVO unavailable / 13.82% |
| 2017-Q30/3 |
LoseCRVO / S&P -28.76% / 4.48% |
LoseCRVO / S&P CRVO unavailable / 5.68% |
LoseCRVO / S&P CRVO unavailable / 17.57% |
| 2017-Q20/3 |
LoseCRVO / S&P -41.60% / 3.09% |
LoseCRVO / S&P CRVO unavailable / 4.83% |
LoseCRVO / S&P CRVO unavailable / 17.74% |
| 2017-Q11/3 |
WinCRVO / S&P 76.55% / 6.07% |
LoseCRVO / S&P CRVO unavailable / 3.67% |
LoseCRVO / S&P CRVO unavailable / 13.32% |
| 2016-Q40/3 |
LoseCRVO / S&P -67.71% / 3.82% |
LoseCRVO / S&P CRVO unavailable / 2.09% |
LoseCRVO / S&P CRVO unavailable / 7.05% |
| 2016-Q30/3 |
LoseCRVO / S&P -12.50% / 3.85% |
LoseCRVO / S&P CRVO unavailable / 0.20% |
LoseCRVO / S&P CRVO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | CRVO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -73.18% | 20.78% |
| Annualized return | -73.18% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | CRVO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -94.07% | 83.14% |
| Annualized return | -43.16% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | CRVO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.97% | 319.30% |
| Annualized return | -56.16% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |